Actively Recruiting
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Led by University Medical Center Groningen · Updated on 2026-04-13
25
Participants Needed
1
Research Sites
167 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
CONDITIONS
Official Title
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with Barrett's esophagus without dysplasia or with suspected or diagnosed low-grade dysplasia, high-grade dysplasia, or superficial esophageal adenocarcinoma
- Planned diagnostic and/or therapeutic endoscopy
- Written informed consent obtained
You will not qualify if you...
- Under 18 years of age
- Submucosal or invasive esophageal adenocarcinoma beyond T1 classification
- Previous radiation therapy for esophageal cancer
- Known allergy to immunoglobulin
- Previous chemotherapy, immunotherapy, related surgery, or prior bevacizumab or cetuximab treatment
- Medical or psychiatric conditions preventing informed consent
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Groningen
Groningen, Provincie Groningen, Netherlands, 9713 GZ
Actively Recruiting
Research Team
W
Wouter B Nagengast, Prof. dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
FACTORIAL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here